$EXAM (ExamWorks Group, Inc.)

$EXAM {{ '2015-11-24T11:38:40+0000' | timeago}} • Announcement

$EXAM closed purchase of business and assets of Argent Rehabilitation Services and Argent Investigation Services for about $53MM cash. $EXAM funded the acquisition with cash on hand. In addition, $EXAM's unit Premex Group entered into two additional national account contracts, which brings its national account total to 6.

$AGN {{ '2017-09-22T21:53:16+0000' | timeago}} • Announcement

$AGN received a Refusal to File letter from the US FDA on its Supplemental New Drug Application (sNDA) for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral antipsychotic approved in the US to treat schizophrenia. The FDA said the sNDA was not sufficient to permit a substantive review.

$AGN {{ '2017-09-22T14:30:34+0000' | timeago}} • Announcement

$AGN announced top-line results from new data for the Centaur Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. $AGN is currently enrolling patients in a 2,000 patient phase 3 clinical trial of CVC called the Aurora trial.

$PRGO {{ '2017-09-21T14:01:01+0000' | timeago}} • Announcement

Healthcare firm $PRGO said the FDA has approved the Abbreviated New Drug Application for its painkiller Exalgo-32mg. Perrigo expects to launch the Exalgo-32mg extended-release tablets by the end of this month. Exalgo is indicated for the management of moderate to severe pain in opioid-tolerant patients.

$CORE {{ '2017-09-21T13:02:10+0000' | timeago}} • Announcement

$CORE, marketers of fresh and broad-line supply solutions to convenience retail industry, has announced that it has renewed its 3-year supply chain agreement with $RAD. Core-Mark is currently providing service to approx 4,500 Rite Aid stores. Finer details of the agreement are under wraps.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$RAD {{ '2017-09-19T15:31:35+0000' | timeago}} • Announcement

Under the amended and restated asset purchase agreement with $RAD, $WBA does not expect the transaction to have a significant impact to its adjusted EPS in FY17. $WBA also expects to realize annual synergies from the transaction of more than $300MM, which are expected to be fully realized within four years of the initial closing of the transaction.

$WBA {{ '2017-09-19T14:19:18+0000' | timeago}} • Announcement

Drugstore chain $WBA, in its fourth attempt, clinched regulatory approval to buy 1,932 stores, 3 distribution centers and related inventory from $RAD for $4.375Bil. The new deal has 250 fewer stores than the earlier deal & is lower than the previous proposal of $5.18Bil. Store purchases would begin in Oct., with completion expected in spring 2018.

$MSA {{ '2017-09-18T17:37:16+0000' | timeago}} • Announcement

$MSA, a safety equipment manufacturer, has elected Bob Leenen as President, MSA International. Leenen succeeds Ronald Herring who will be retiring in Oct. He will be responsible for business interests outside of North America and South America, and based in Rapperswil-Jona, Switzerland.

$PRGO {{ '2017-09-18T13:18:23+0000' | timeago}} • Announcement

$PRGO has received tentative approval from the US FDA for the generic version of Acanya topical gel 1.2%/ 2.5%, for the topical treatment of acne in patients 12 years or older.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$CVS {{ '2017-09-14T16:58:01+0000' | timeago}} • Announcement

$CVS said it will acquire six Ohio outpatient pharmacy locations from ProMedica, and plans to close five of them. The facility will transition to become a CVS Pharmacy in early November.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$CVS {{ '2017-09-07T14:27:45+0000' | timeago}} • Announcement

CVS Pharmacy, the retail division of $CVS, said it is introducing automated retail vending machines stocked with convenient, on-the-go necessities including over-the-counter health products, "better-for-you" snacks and popular personal care products typically sold at CVS Pharmacy locations nationwide.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$AGN {{ '2017-08-29T10:53:21+0000' | timeago}} • Announcement

$AGN and its subsidiaries reached a settlement regarding its litigation with Famy Care Ltd. relating to the company's patent covering Restasis (Cyclosporine Ophthalmic Emulsion). All Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review.

$PETS {{ '2017-08-24T14:54:20+0000' | timeago}} • Announcement

Faruqi & Faruqi LLP, a national securities law firm, is investigating potential misconduct at $PETS. The investigation focuses on whether the BoD or officers committed mismanagement and breached their fiduciary duties. Some reports claim that $PETS engaged in online advertising to market dangerous painkillers to human opiate addicts and drug users.

$PRGO {{ '2017-08-21T17:07:39+0000' | timeago}} • Announcement

$PRGO got the final nod from the FDA for the store brand OTC equivalent of Nexium 24HR (esomeprazole magnesium) capsules, to treat frequent heartburns occurring 2 or more days a week.  It also reached a settlement of patent litigation with AstraZeneca allowing for the store brand OTC equivalent of Nexium 24HR capsules to launch in Sept, 2017.

Recent Transcripts

NVO (Novo Nordisk A/S)
Thursday, August 10 2017 - 12:15pm
PRGO (Perrigo Company Public Limited Company)
Thursday, August 10 2017 - 12:00pm
PRSC (Providence Service Corp.)
Wednesday, August 9 2017 - 12:00pm
NVO (Novo Nordisk A/S)
Wednesday, August 9 2017 - 11:00am
OPK (Opko Health, Inc.)
Tuesday, August 8 2017 - 8:30pm
CVS (CVS Health Corporation)
Tuesday, August 8 2017 - 12:30pm
MSA (MSA Safety Incorporated)
Friday, August 4 2017 - 12:30pm
LHCG (LHC Group, Inc.)
Thursday, August 3 2017 - 3:00pm
USPH (US Physical Therapy Inc.)
Thursday, August 3 2017 - 2:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
MOH (Molina Healthcare, Inc.)
Wednesday, August 2 2017 - 9:00pm
NUS (Nu Skin Enterprises Inc.)
Wednesday, August 2 2017 - 9:00pm
OMI (Owens & Minor Inc.)
Wednesday, August 2 2017 - 12:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
CHE (Chemed Corp.)
Wednesday, July 26 2017 - 2:00pm
PETS (PetMed Express, Inc.)
Monday, July 24 2017 - 12:30pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
PRGO (Perrigo Company Public Limited Company)
Wednesday, May 31 2017 - 12:30pm
PMC (PharMerica Corporation)
Wednesday, May 10 2017 - 2:00pm

AlphaGraphics you may like